(:EYES)

Business Focus: N/A

Aug 31, 2022 06:00 am ET

Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the “Company” or “Vivani”) announced that trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “VANI” will commence today.

Aug 30, 2022 06:00 am ET

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. (“NPM”). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.

Jul 29, 2022 06:00 am ET

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission.

Jul 18, 2022 06:00 am ET

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (“NIH”) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the “Orion Trial”), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and

Apr 14, 2022 08:00 am ET

Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight”), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. (“NPM”), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.

Feb 21, 2022 08:00 am ET

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ECOL, ZWS, MGI, TLMD, EYES

NEW YORK, Feb. 21, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Feb 20, 2022 01:07 am ET

Lifshitz Law PLLC Announces Investigation of POND, EPAY, EYES and TLMD

Angel Pond Holdings Corporation (NYSE: POND) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the merger of POND and MariaDB Corporation. If you are an investor, and would like information...

Feb 17, 2022 03:12 pm ET

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates EYES, LAWS, EPAY, GCP

Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Second Sight Medical Products, Inc....

Feb 16, 2022 10:24 pm ET

SECOND SIGHT MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Second Sight Medical Products, Inc. - EYES

NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Second Sight Medical Products, Inc. ("the Company") (NasdaqCM: EYES) with Nano Precision Medical, Inc. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company's shareholders.

Feb 15, 2022 04:36 pm ET

Moore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law Firm

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Feb 14, 2022 08:30 am ET

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ECOL, EYES, ZGNX, FLMN

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Feb 13, 2022 01:08 am ET

Lifshitz Law PLLC Announces Investigation of SYTE, EYES, ECOL, and VCRA

Enterprise Diversified, Inc. (OTC: SYTE) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the merger of SYTE and CrossingBridge Advisors, LLC. If you are an investor, and would like...

Feb 12, 2022 12:19 am ET

Equity Alert - The M&A Class Action Firm is Investigating the Merger - SAVE, ECOL, EYES, VHAQ, BREZ, AKIC

NEW YORK, Feb. 12, 2022 /PRNewswire/ --

Feb 09, 2022 04:43 pm ET

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SAVE, TLMD, ALJJ, ECOL, EYES

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties relating to:

Feb 09, 2022 01:34 pm ET

EYES Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Second Sight Medical Products, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Second Sight Medical Products, Inc. (NASDAQ: EYES) and Nano Precision Medical, Inc. is fair to Second Sight shareholders.

Feb 07, 2022 04:30 pm ET

Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and device medical implants that treat chronic diseases with high unmet medical need.

Aug 11, 2021 06:00 am ET

Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk/benefit balance for

Jun 25, 2021 01:39 pm ET

Second Sight Medical Products Announces Closing of Public Offering

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriter’s option to purchase additional shares. The gross proceeds from the offering, including the exercise of the over-allotment op

Jun 22, 2021 08:59 pm ET

Second Sight Medical Products Announces Pricing of Public Offering

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,

Jun 22, 2021 04:39 pm ET

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jun 01, 2021 06:00 am ET

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

May 13, 2021 06:00 am ET

Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant UH3NS103442. The NIH released $1.4 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Bay

May 12, 2021 06:00 am ET

Second Sight Medical Products Announces Two-Year Results of its Orion Study

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion). The Study is a single arm six subject study at UCLA and Baylor College of Medicine. The Study was paused due to the COVID-19 pandemic, but is now resumed at both centers. All subjects are still enrolled in the Study and recent visual funct

Apr 06, 2021 08:00 am ET

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company’s Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board.

Apr 01, 2021 08:00 am ET

Second Sight Medical Products Names Scott Dunbar Acting CEO

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company’s Board of Directors has named Scott Dunbar to replace Matthew Pfeffer as acting Chief Executive Officer (“CEO”). Under Nasdaq rules, an independent director may temporarily be named acting CEO, but such service cannot continue for more than one year. Accordingly, Mr. Pfeffer has relinquished the role of acting CEO but will r

Mar 26, 2021 05:00 pm ET

Second Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has closed its previously announced private placement, which resulted in gross proceeds to Second Sight of $27.9 million, before deducting offering expenses. The net proceeds from the private placement are expected to provide working capital for the Company.

Mar 24, 2021 07:00 am ET

Second Sight Medical Products Announces $27.9 Million Private Placement of Common Stock

Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into definitive securities purchase agreements with accredited investors for a private placement that will result in gross proceeds to Second Sight of $27.9 million, before deducting placement offering expenses. Second Sight will issue 4,650,000 shares of common stock at a price of $6.00 per share. This private placement

Mar 05, 2021 08:00 am ET

Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System

Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next ge

Sep 22, 2020 08:00 am ET

Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA

Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion

May 05, 2020 01:08 pm ET

Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock

Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it closed its previously announced underwritten public offering of 7,500,000 shares of common stock at an o

Apr 30, 2020 08:43 pm ET

Second Sight Medical Products Announces Pricing of Public Offering of Common Stock

Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of an underwritten public offering of 7,500,000 shares of common stock, no par value (the “Common St

Apr 28, 2020 08:00 am ET

Second Sight Medical Products Provides Business Update

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today that the Company has taken significant steps to reduce overhead and conserve liquidity as it continues operations while assessing strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not b

Mar 30, 2020 01:15 pm ET

Second Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that in response to the impact of the global COVID-19 pandemic on its ability to secure financing, the Company will lay off approximately 84 of its 108 employees effective March 31, 2020. The impacted employees will be eligible for unemployment benefits subject to local regulations. Against a background of unprecedented economic shock caused

Mar 19, 2020 04:05 pm ET

Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 16, 2020 08:00 am ET

Second Sight to Discuss Fourth Quarter and Year-End 2019 Financial Results on March 19, 2020 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. financial markets.

Mar 12, 2020 04:15 pm ET

Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the departure of Will McGuire, President and Chief Executive Officer (“CEO”), effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board.

Nov 14, 2019 04:05 pm ET

Second Sight Reports Third Quarter 2019 Financial Results

Nov 05, 2019 04:30 pm ET

Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its financial results for the third quarter of 2019 on Thursday, November 14, 2019, after the close of the U.S. financial markets.

Oct 01, 2019 08:00 am ET

Second Sight Announces $2.4 Million, Four-Year Grant from National Institutes of Health to Develop Spatial Localization and Mapping Technology

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the “Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced receipt of a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is intended to speed the integration of SLAM into next generation versions of the C

Aug 28, 2019 08:00 am ET

Second Sight to Present at September Investor Conferences

Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics today announced that Will McGuire, President and Chief Executive Officer, and John Blake, Chief Financial Officer, are scheduled to present at three upcoming conferences as follows:

Aug 06, 2019 04:05 pm ET

Second Sight Reports Second Quarter 2019 Financial Results

Recent Financial and Corporate Highlights:

Jul 30, 2019 04:30 pm ET

Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its financial results for the second quarter of 2019 on Tuesday, August 6, 2019, after the close of the U.S. financial markets.

Jun 25, 2019 04:05 pm ET

Researchers Present Latest Positive Results of Second Sight’s Orion Visual Cortical Prosthesis Feasibility Study

The study’s principal investigators, Nader Pouratian, MD, Ph.D. of Ronald Reagan UCLA Medical Center (“UCLA”), and Daniel Yoshor, MD of Baylor College of Medicine (“Baylor”), are presenting the topline data. Orion is a breakthrough technology intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion converts images captured by a miniature video camera mounted on glasses into a series of small electrical pulses transmitted wirelessly to electrodes implant

May 16, 2019 05:00 pm ET

Second Sight to Present at 20th Annual B. Riley FBR Investor Conference

May 15, 2019 04:05 pm ET

Second Sight Reports First Quarter 2019 Financial Results

May 15, 2019 04:01 pm ET

Second Sight to Accelerate Development of Orion® Visual Cortical Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System (“Orion”). Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retinopathy, optic nerve

May 08, 2019 08:00 am ET

Second Sight to Discuss First Quarter 2019 Financial Results on May 15, 2019 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its financial results for the first quarter of 2019 on Wednesday, May 15, 2019, after the close of the U.S. financial markets.

Apr 18, 2019 07:45 am ET

New Research Coverage Highlights Sequential Brands Group, White Mountains Insurance Group, PetIQ, Black Stone Minerals, Second Sight Medical Products, and USA Truck — Consolidated Revenues, Company Gr

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sequential Brands Group, Inc. (NASDAQ:SQBG), White Mountains Insurance...

Apr 11, 2019 08:00 am ET

Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative® Investigators Meeting

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company will present an update on its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at the Fifth Annual BRAIN Initiative® Investigators Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. on April 11,

Mar 13, 2019 04:05 pm ET

Second Sight Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 06, 2019 08:00 am ET

Second Sight to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 Conference Call

Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its 2018 fourth quarter and year-end financial results on Wednesday, March 13, 2019, after the close of the U.S. financial markets.

Feb 21, 2019 06:06 pm ET

Second Sight Medical Products, Inc. Announces Completion of Rights Offering

Jan 22, 2019 07:35 am ET

Recent Analysis Shows Abercrombie & Fitch, DaVita, W.W. Grainger, Ingredion, FirstEnergy, and Second Sight Medical Products Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Abercrombie & Fitch Company (NYSE:ANF), DaVita Inc. (NYSE:DVA), W.W....

Jan 07, 2019 08:05 am ET

Second Sight Medical Products, Inc. Announces $40 Million Rights Offering of Units and Two Year Extension of Warrants (EYESW) Expiration Date

Jan 07, 2019 08:00 am ET

Second Sight Reports Fourth Quarter 2018 Business Update

Dec 20, 2018 08:00 am ET

Second Sight to Present at Digital Medicine and Medtech Showcase 2019

Dec 14, 2018 08:00 am ET

Second Sight Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

Nov 27, 2018 04:30 pm ET

Second Sight to Present at the 11th Annual LD Micro Main Event Conference in Los Angeles on Wednesday, December 5th

Nov 12, 2018 08:15 am ET

Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forwar

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Prudential Financial, Inc. (NYSE:PRU), Second Sight Medical Products,...

Nov 07, 2018 04:01 pm ET

Second Sight Reports Third Quarter 2018 Financial Results

Nov 06, 2018 04:01 pm ET

Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System

Oct 30, 2018 08:00 am ET

Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter financial results on Wednesday, November 7, 2018, after the close of the U.S. financial markets.

Oct 22, 2018 09:00 am ET

Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that it has entered into a stock purchase agreement effective October 18, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors of Second Sight, for the purchase of 2,467,727 shares of common stock priced at $1.62 per share, the last reported sale pric

Oct 18, 2018 08:30 am ET

New Research Coverage Highlights QuinStreet, Senseonics, Ring Energy, Blue Apron, Second Sight Medical Products, and Real Goods Solar — Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of QuinStreet, Inc. (NASDAQ:QNST), Senseonics Holdings, Inc. (NYSE:SENS),...

Sep 18, 2018 08:00 am ET

Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that the Company has received a $1.6 million grant (with the intent to fund $6.3 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in Janu

Sep 04, 2018 08:00 am ET

Second Sight Appoints Pat Ryan Chief Operating Officer

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Materials, Quality Assurance, and Information Technology. He will report to Will McGuire, Secon

Aug 27, 2018 07:40 am ET

Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C Energy Services, Inc. (NYSE:CJ), LivePerson, Inc. (NASDAQ:LPSN),...

Aug 22, 2018 08:00 am ET

Second Sight to Present at Investor Conferences in September

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and Chief Executive Officer, and John Blake, Chief Financial Officer, are scheduled to present at two upcoming conferences as follows:

Aug 16, 2018 08:00 am ET

Second Sight Completes $5.0 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that it has entered into a stock purchase agreement effective August 14, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors, for the purchase of 3,225,807 shares of common stock priced at $1.55 per share, the last reported sale price of the common stoc

Aug 07, 2018 04:05 pm ET

Second Sight Reports Second Quarter 2018 Financial Results

Jul 31, 2018 08:00 am ET

Second Sight to Discuss Second Quarter 2018 Financial Results on August 7, 2018 Conference Call

Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its 2018 second quarter financial results on Tuesday, August 7, 2018, after the close of the U.S. financial markets.

Jun 21, 2018 08:25 am ET

Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark Therapeutics, Natera, and Kadmon — Research Highlights Growth, Revenue, and Consolidated Re

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Second Sight Medical Products, Inc. (NASDAQ:EYES), ICF International, Inc....

May 14, 2018 08:00 am ET

Second Sight Medical Products, Inc. to Present at the 19th Annual B. Riley FBR Investor Conference

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and Chief Executive Officer, and John T. Blake, Chief Financial Officer, will present at the 19th Annual B. Riley FBR Investor Conference as follows:

May 10, 2018 04:01 pm ET

Second Sight Reports First Quarter 2018 Financial Results

May 07, 2018 08:00 am ET

Second Sight Completes $10 Million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that it has entered into a stock purchase agreement on May 3, 2018 with entities beneficially owned by Gregg Williams for the purchase of 6,756,757 shares of common stock priced at $1.48 per share, the last reported sale price of the common stock on that date. Gregg Williams is Chairman of

May 03, 2018 05:00 pm ET

Second Sight to Discuss First Quarter 2018 Financial Results on May 10, 2018 Conference Call

Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, will release its 2018 first quarter financial results on Thursday, May 10, 2018, after the close of the U.S. financial markets.

May 01, 2018 08:10 am ET

Research Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook — Fundamental Analysis, Cal

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Flexsteel Industries, Inc. (NASDAQ:FLXS), Second Sight...

Apr 09, 2018 04:30 pm ET

Second Sight Announces Dr. Robert Greenberg’s Resignation from Board of Directors and as an Officer of the Company

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Dr. Robert Greenberg, MD, PhD has resigned from the Company’s Board of Directors and the Company, effective April 3, 2018. Dr. Robert Greenberg has served on the Board of Directors since May 2003, as Chief Executive Officer from December 1998 to August 2015, and as Chairman of the Board

Mar 22, 2018 08:00 am ET

Second Sight Appoints John T. Blake Chief Financial Officer

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that John T. Blake has been appointed Chief Financial Officer, effective immediately. Mr. Blake succeeds Thomas Miller, who has served as Chief Financial Officer since 2014. In June 2017, Mr. Miller submitted his resignation to pursue other opportunities but agreed at our request to remain in

Mar 19, 2018 07:30 am ET

Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook — Fundamental Analysis, Calcu

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Hancock Holding...

Mar 16, 2018 08:00 am ET

Second Sight Appoints Gregg Williams as Chairman of the Board of Directors

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Board of Directors has appointed Mr. Gregg Williams as Chairman of the Board, effective immediately. Mr. Williams, a current member of the Board of Directors of Second Sight and the Company’s largest shareholder succeeds Dr. Robert “Bob” Greenberg, who has served as Chairman of the B

Mar 08, 2018 04:30 pm ET

Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering Symposium

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and Chief Executive Officer, will present at the B. Riley & Co. China Healthcare Investment Partnering Symposium as follows:

Mar 07, 2018 04:05 pm ET

Second Sight Reports Fourth Quarter and Full Year 2017 Financial Results

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today reported financial results for the three- and twelve-month periods ended December 31, 2017.

Mar 06, 2018 08:00 am ET

Second Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, today announced that Palmetto GBA (Jurisdiction JJ) is the latest Medicare Administrative Contractor (MAC) to provide coverage for the Argus® II Retinal Prosthesis System (Argus II) and the related surgical procedure. As a result of this decision, coverage for the Argus II will now include Alabama,

Mar 05, 2018 08:00 am ET

Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on March 7, 2018

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Dr. Robert Greenberg, Chairman of the Board, Will McGuire, President and Chief Executive Officer, and Thomas Miller, Chief Financial Officer, will present an overview of the business model, growth initiatives and key milestones, and answer questions from investors via webcast at the LD

Feb 28, 2018 08:00 am ET

Second Sight to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018 Conference Call

Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, will release its fourth quarter and year-end financial results on Wednesday, March 7, 2018, after the close of the U.S. financial markets.

Feb 16, 2018 08:00 am ET

Second Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, today announced market entry into Singapore, with the first patient implanted with the Company’s Argus® II Retinal Prosthesis System (“Argus II”). The implantation was facilitated by the Company’s exclusive distribution partner in Singapore, Mandarin Opto-Medic Co Pte Ltd.

Feb 05, 2018 08:00 am ET

Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today provided an update on several key performance metrics, demonstrating the Company’s continued progress in executing its near- and long-term goals.

Jan 09, 2018 08:30 am ET

Investor Expectations to Drive Momentum within Cutera, Matrix Service, PRA Group, Materion, Second Sight Medical Products, and Syndax Pharmaceuticals — Discovering Underlying Factors of Influence

NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cutera, Inc. (NASDAQ:CUTR), Matrix Service Company...

Dec 05, 2017 09:00 am ET

Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced market entry into Iran, implanting the first two patients with the Company’s Argus® II Retinal Prosthesis System (“Argus II”). The implant was facilitated by the country’s exclusive distribution partner, Arshia Gostar Darman Co. Ltd.

Nov 10, 2017 08:00 am ET

Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Argus II® Retinal Prosthesis System ("Argus II") has been recommended for public funding by the Ontario Health Technology Advisory Committee (OHTAC) of Health Quality Ontario. The recommendation has been forwarded to the Ontario Minister of Health and Long-Term Care.

Nov 08, 2017 08:00 am ET

Second Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Expedited Access Pathway designation for the Orion™ Cortical Visual Prosthesis System (Orion). This designation is given to a few select medical devices in order to provide more effective treatment of life-threatening or irreversibly

Nov 02, 2017 04:00 pm ET

Second Sight Reports Third Quarter 2017 Financial Results

Nov 02, 2017 08:05 am ET

Second Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Company has received full approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The approval allows two U.S. sites, the University of California at Los Angeles (UCLA) and Baylor College of

Nov 02, 2017 08:00 am ET

Second Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Centers for Medicare & Medicaid Services (CMS) finalized its Medicare hospital outpatient payment rate of $122,500 for the Argus® II Retinal Prosthesis System (Argus II) procedure for calendar year 2018. The payment for the surgical procedure includes the cost of the Argus II.

Oct 26, 2017 08:00 am ET

Second Sight to Discuss Third Quarter 2017 Financial Results on November 2, 2017 Conference Call

Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its third quarter 2017 financial results on Thursday, November 2, 2017, after the close of the U.S. financial markets.

Oct 19, 2017 07:00 am ET

Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that provide useful vision to blind patients, today announced the appointment of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific, where he will lead all commercial activities for the Company outside of North America.

Oct 17, 2017 07:00 am ET

Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa Patients

Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received approval from Bundesinstitut für Arzneimittel und Medizinprodukte (“BfArM”), the German competent authority, and a favorable opinion by the applicable ethics committees, to begin a 10-patient study in Germany to implant and evaluate the Argus® II Retinal Prosthesis System (“Argus II”) in bet

Jul 25, 2016 03:57 pm ET

Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System

SYLMAR, California, July 25, 2016 /PRNewswire/ --

Mar 09, 2016 09:31 am ET

Covered Call Alerts For Amazon.com, LinkedIn, Bitauto Holdings, CableVision Systems and Second Sight Medical Products Inc. Released By InvestorsObserver

CHICAGO, March 9, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, LNKD, BITA, CVC and EYES.

Feb 23, 2016 12:37 pm ET

Covered Call Alerts For PayPal Holdings Inc., 3D Systems, Exact Sciences, Second Sight Medical Products Inc. and Gogo Incorporated Released By InvestorsObserver

CHICAGO, Feb. 23, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PYPL, DDD, EXAS, EYES and GOGO.

You are here

(:EYES)

Business Focus: N/A